Pfizer Inks Deal to Sell More Generics – From Aurobindo Pharma in India

39 Generic Drugs to be sold in the US, and 12 injectable drugs are part of the deal. Pfizer is not alone, other pharma companies are doing the same as drug patents are getting closer to expiring. In the meantime, we have this inquiry going on over at Harvard. It looks like it’s getting too expensive to contribute to the teaching hospitals and medical centers in the US, much less the administrative time to calculate what you did, how you did it, and how much it costs.

Not to downplay honesty by any means, but conflict of interest payments are the concern here, but Harvard is not alone, you can find this anywhere and with other drug companies too. With technology, there’s a great way to track all of this from here on out with audit trails, etc., but again some may have gone on behind the scenes and we many not be privy to the entire situation, so it looks like to China and India they go, not only generics, but also a lot of R and D and clinical trials have already moved overseas from the US.

In a related post, we have former Pfizer whistle blower Dr. Peter Rost who certainly wants to be in the running for the FDA commissioner job. The two hottest trends in healthcare are still whistle blowers and algorithms. BD

Peter Rost for FDA Commissioner – Read up and see what you think

The company said today it has inked a set of deals with Indian generics maker Aurobindo Pharma for rights to 39 generic oral drugs in the U.S. and 31 in Europe, including 11 in France alone. The drugs are for heart disease and neurological disorders, among other things. The company will sell the drugs in the U.S. through its Greenstone generics unit.

Pfizer also acquired rights to 12 injectable antibiotics in the U.S. and Europe. Pfizer didn’t disclose the deal terms but said the agreements expanded a five-product U.S. deal entered into with Aurobindo in July.

Health Blog : Pfizer Grabs Rights to Sell More Generics

Related Reading: